Companies: 10,795·Total market cap: $144.5T
Gelesis Holdings, Inc.

Gelesis Holdings, Inc.

GLSNYSEHealthcare
$0.16
+$0.00(+0.00%)
Market Cap$11630550
P/E Ratio
52W High$5.67
52W Low$0.012

Gelesis Holdings, Inc. (GLS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

gls · pe ratio · data through Dec 31, 2022

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Gelesis Holdings, Inc. (GLS) measures how much investors pay for each dollar of the company's trailing earnings. GLS's current PE ratio of N/A is calculated by dividing its stock price of $0.16 by its TTM earnings per share of -$0.79.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31

Forward P/E
N/A
EPS (TTM)
-$0.79
TTM · diluted EPS
PEG Ratio
0.01
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gelesis Holdings, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2020 – 2022 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Gelesis Holdings, Inc.
Gelesis Holdings, Inc.You
GLS
$12MN/A-$0.79
Applied Molecular Transport Inc.
Applied Molecular Transport Inc.
AMTI
$11MN/A-$3.23
Axcella Health Inc.
Axcella Health Inc.
AXLA
$13MN/A-$1.27
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
CYCC
$11MN/A-$1.37
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
HURA
$132MN/A-$0.63
Korro Bio, Inc.
Korro Bio, Inc.
KRRO
$110MN/A-$12.48
Notable Labs, Ltd.
Notable Labs, Ltd.
NTBL
$2MN/A-$5.03

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 3 of 3 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2022-12-31Latest
FY2022
$-0.79
2021-12-31
FY2021
$-16.34
2020-12-31
FY2020
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Gelesis Holdings, Inc. (GLS) measures how much investors pay for each dollar of the company's trailing earnings. GLS's current PE ratio of N/A is calculated by dividing its stock price of $0.16 by its TTM earnings per share of -$0.79.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.16 ÷ -$0.79 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

GLS pe ratio · 6 questions

GLS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.16 and TTM EPS of -$0.79. Data sourced from Financial Modeling Prep via GLS's SEC 10-K and 10-Q filings.

GLS PE ratioWhat is GLS PE ratioCurrent PE ratio of GLSGLS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gelesis Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09